医学
间充质干细胞
冠状动脉疾病
心脏病学
射血分数
内科学
心绞痛
祖细胞
加拿大心血管学会
血运重建
细胞疗法
外科
心力衰竭
干细胞
心肌梗塞
病理
生物
遗传学
作者
Tina Friis,Mandana Haack-Sørensen,Anders Bruun Mathiasen,Rasmus S. Ripa,Ulrik Sloth Kristoffersen,Erik Jørgensen,Louise Hansen,Lene Bindslev,Andreas Kjaer,Birger Hesse,Ebbe Dickmeiss,Jens Kastrup
标识
DOI:10.3109/14017431.2011.569571
摘要
Aims. We evaluated the feasibility, safety and efficacy of intra-myocardial injection of autologous mesenchymal stromal cells derived endothelial progenitor cell (MSC) in patients with stable coronary artery disease (CAD) and refractory angina in this first in man trial. Methods and results. A total of 31 patients with stable CAD, moderate to severe angina and no further revascularization options, were included. Bone marrow MSC were isolated and culture expanded for 6–8 weeks. It was feasible and safe to establish in-hospital culture expansion of autologous MSC and perform intra-myocardial injection of MSC. After six months follow-up myocardial perfusion was unaltered, but the patients increased exercise capacity (p < 0.001), reduction in CCS Class (p < 0.001), angina attacks (p < 0.001) and nitroglycerin consumption (p < 0.001), and improved Seattle Angina Questionnaire (SAQ) evaluations (p < 0.001). For all parameters there was a tendency towards improved outcome with increasing numbers of cells injected. In the MRI substudy: ejection fraction (p < 0.001), systolic wall thickness (p = 0.03) and wall thickening (p = 0.03) all improved. Conclusions. The study demonstrated that it was safe to treat patients with stable CAD with autologous culture expanded MSC. Moreover, MSC treated patients had significant improvement in left ventricular function and exercise capacity, in addition to an improvement in clinical symptoms and SAQ evaluations.Trial registration: ClinicalTrials.gov identifier: NCT00260338.
科研通智能强力驱动
Strongly Powered by AbleSci AI